• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

139
19
13
13
11

COUNTRY

5
4
4
4
3

PRICE

6
90
122
496

PUBLISHED

1
13
123
496

PRODUCT TYPE

488
5
2
1

Immune Disorders

(496 Products)

More than 150 primary immunodeficiency diseases (PIDs) have been identified, a number that does not include acquired immunodeficiencies. Examples of immune disorders include Type 1 diabetes, rheumatoid arthritis, allergies, Crohn’s Disease, and HIV, which infects over 0.5% of the world’s population.

In the reports and subscriptions listed under Research and Markets’ category you will find pipeline assessments of drugs and therapeutics, market forecasts, investment and growth opportunities, and much more. Also explored in-depth is the key role of immune response and pharmaceuticals in transplant medicine, with reviews of clinical trials, market trends and major companies in the areas of lung transplants, liver transplants, transplant inflammation/rejection, etc.

Key players profiled include Abbott Laboratories, Pfizer, Johnson & Johnson, Biogen Idec, Amgen, Bayer AG, Sanofi, and more. Show Less
Read more

PRODUCT TITLE

Simponi (golimumab) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

Simponi (golimumab) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023 Summary Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints....

December 2014
FROM

Tregalizumab (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

Tregalizumab (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023 Summary Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints ....

December 2014
FROM

Mavrilimumab (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

Mavrilimumab (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023 Summary Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints ....

December 2014
FROM

Actemra/ RoActemra (tocilizumab) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

Actemra/ RoActemra (tocilizumab) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023 Summary Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity...

December 2014
FROM

Xeljanz (tofacitinib) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

Xeljanz (tofacitinib) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023 Summary Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the...

December 2014
FROM

PharmaPoint: Rheumatoid Arthritis - India Drug Forecast and Market Analysis to 2023

PharmaPoint: Rheumatoid Arthritis - India Drug Forecast and Market Analysis to 2023 Summary Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the...

December 2014
FROM

PharmaPoint: Rheumatoid Arthritis - Japan Drug Forecast and Market Analysis to 2023

PharmaPoint: Rheumatoid Arthritis - Japan Drug Forecast and Market Analysis to 2023 Summary Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the...

December 2014
FROM

PharmaPoint: Rheumatoid Arthritis - China Drug Forecast and Market Analysis to 2023

PharmaPoint: Rheumatoid Arthritis - China Drug Forecast and Market Analysis to 2023 Summary Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the...

December 2014
FROM

PharmaPoint: Rheumatoid Arthritis - Australia Drug Forecast and Market Analysis to 2023

PharmaPoint: Rheumatoid Arthritis - Australia Drug Forecast and Market Analysis to 2023 Summary Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of...

December 2014
FROM

PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2023 Summary Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the...

December 2014
FROM

PharmaPoint: Rheumatoid Arthritis - 5EU Drug Forecast and Market Analysis to 2023

PharmaPoint: Rheumatoid Arthritis - 5EU Drug Forecast and Market Analysis to 2023 Summary Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints....

December 2014
FROM

Baricitinib (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

Baricitinib (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023 Summary Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints ....

December 2014
FROM

Filgotinib (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

Filgotinib (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023 Summary Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It...

December 2014
FROM

Decernotinib (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

Decernotinib (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023 Summary Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints ....

December 2014
FROM

Sjogren's Syndrome Global Clinical Trials Review, H2, 2014

Sjogren's Syndrome Global Clinical Trials Review, H2, 2014 Summary Our clinical trial report, “Sjogren's Syndrome Global Clinical Trials Review, H2, 2014" provides data on the Sjogren’s Syndrome clinical...

December 2014
FROM

Sarcoidosis - Pipeline Review, H2 2014

Sarcoidosis - Pipeline Review, H2 2014 Summary This, ‘Sarcoidosis - Pipeline Review, H2 2014’, provides an overview of the Sarcoidosis’s therapeutic pipeline. This report provides comprehensive information...

December 2014
FROM

Myasthenia Gravis - Pipeline Review, H2 2014

Myasthenia Gravis - Pipeline Review, H2 2014 Summary This, ‘Myasthenia Gravis - Pipeline Review, H2 2014’, provides an overview of the Myasthenia Gravis’s therapeutic pipeline. This report provides...

December 2014
FROM

Cedar Pollen Allergy - Pipeline Review, H2 2014

Cedar Pollen Allergy - Pipeline Review, H2 2014 Summary This, ‘Cedar Pollen Allergy - Pipeline Review, H2 2014’, provides an overview of the Cedar Pollen Allergy’s therapeutic pipeline. This report...

December 2014
FROM

EpiCast Report: Rheumatoid Arthritis - Epidemiology Forecast to 2023

EpiCast Report: Rheumatoid Arthritis - Epidemiology Forecast to 2023 Summary Rheumatoid arthritis (RA) is an autoimmune disease that causes inflammation of the joints. In RA, the body’s immune system...

December 2014
FROM
Immunology Bundle 2014 Immunology Bundle 2014 - Product Thumbnail Image

Immunology Bundle 2014

Available until the 31st of December only, we bring you the most popular seven publications from the immunology sector. Carefully hand-picked by the publisher, we are offering over 4000+ pages of information...

December 2014
Loading Indicator

Our Clients

Merck & Co., Inc. Celgene Corporation GlaxoSmithKline PLC Genentech, Inc. Johnson & Johnson Services, Inc. ViiV Healthcare